New Dosing Schedule for Ropeginterferon Alfa-2b Shows Improved Efficacy in Polycythemia Vera

New ropeginterferon alfa-2b Data Suggest Alternate Dosing Schedule May Achieve Greater and Quicker Complete Hematologic and Molecular Responses in Polycythemia Vera PharmaEssentia Corporation (TPEx:6446), a leading fully integrated biopharmaceutical company in Taiwan, announced today the publication of new results from a Phase 2 clinical study with ropeginterferon alfa-2b, marketed as BESREMi®, ..